A clinical study on primary hypothyroidism and its treatment with a Unani drug.

A clinical study on the management of primary hypothyroidism with a unani polyherbal formulation-An open label single arm study.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/04/041632

Enrollment

Registered

2022-04-04

Start date

Unknown

Completion date

Unknown

Last updated

2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E039- Hypothyroidism, unspecified

Interventions

Intervention1: Extract of Unani Polyherbal Formulation -Bisbasa (Myristica fragrans), Zanjbeel (Zingiber officinalis), Asarun (Asarum europaeum), Filfil Siyah (Piper nigrum), Qaranfal (Szygium aromati

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosed cases of Primary Hypothyroidism with TSH level >20mIU/L. Patient willing to participate and sign the consent form. Patient willing to discontinue the drugs taking for the treatment of Primary Hypothyroidism.

Exclusion criteria

Exclusion criteria: Patient unwilling to sign the consent form. Patient taking hormonal therapy. Pregnant and lactating women. Renal and hepatic insufficiency and malignancy. Patient with tachyarrhythmia. Patient with increased bowel movements. Patient with menorrhagia, metrorrhagia and polymenorrhea. Patient with parkinsonism and tremors.

Design outcomes

Primary

Measure	Time frame
TSH, Free T3 & T4 Tiredness Loss of appetite Cold intolerance Constipation Sleep will be assessed. Timepoint: 6 Week	—

Secondary

Measure	Time frame
Lipid Profile and Quality of Life will be assessedTimepoint: 6 Week	—

Countries

India

Contacts

Public ContactDr Saema Khanam

Ayurvedic and Unani Tibbia College and Hospital

drrahman002@gmail.com9313980776

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026